In conclusion, the present study demonstrates that GPC3 expression induces T cell-mediated immune response in this mouse ovarian cancer model and also provides supportive evidence that GPC3 is an ideal target for ovarian cancer immunotherapy. This evidence concerns the gene GPC3 and ovarian carcinoma.